RESUMO
OBJECTIVE: To validate the BED capture enzyme immunoassay for HIV-1 subtype C and to derive adjustments facilitating estimation of HIV-1 incidence from cross-sectional surveys. DESIGN: Laboratory analysis of archived plasma samples collected in Zimbabwe. METHODS: Serial plasma samples from 85 women who seroconverted to HIV-1 during the postpartum year were assayed by BED and used to estimate the window period between seroconversion and the attainment of a specified BED absorbance. HIV-1 incidences for the year prior to recruitment and for the postpartum year were calculated by applying the BED technique to HIV-1-positive samples collected at baseline and at 12 months. RESULTS: The mean window for an absorbance cut-off of 0.8 was 187 days. Among women who were HIV-1 positive at baseline and retested at 12 months, a proportion (epsilon) 5.2% (142/2749) had a BED absorbance < 0.8 at 12 months and were falsely identified as recent seroconverters. Consequently, the estimated BED annual incidence at 12 months postpartum (7.6%) was 2.2 times the contemporary prospective estimate. BED incidence adjusted for epsilon was 3.5% [95% confidence interval (CI), 2.6-4.5], close to the 3.4% estimated prospectively. Adjusted BED incidence at baseline was 6.0% (95% CI, 5.2-6.9) and, like the prospective estimates, declined with maternal age. Unadjusted BED incidence estimates were largely independent of age; the pooled estimate was 58% higher than adjusted incidence. CONCLUSION: The BED method can be used in an African setting, but further estimates of epsilon and of the window period are required, using large samples in a variety of circumstances, before its general utility can be gauged.
Assuntos
Sorodiagnóstico da AIDS/métodos , Infecções por HIV/epidemiologia , HIV-1 , Complicações Infecciosas na Gravidez/epidemiologia , Métodos Epidemiológicos , Feminino , Humanos , Técnicas Imunoenzimáticas/métodos , Imunoglobulina G/sangue , Gravidez , Zimbábue/epidemiologiaRESUMO
Synthetic peptides have frequently replaced the more costly recombinant proteins or viral lysates as the antigens of choice for detection of antibodies to human immunodeficiency viruses. However, development of an assay that is sensitive to all the types and groups of HIV, including the divergent strains of HIV-1 group O, group N, and HIV-2, would require many peptides derived from different types and groups of HIV. Combining multiple peptide antigens may reduce the analytical sensitivity of the individual peptide due to the competition for binding to the solid surface when used in an enzyme immunoassay format. In this study, we developed and evaluated two chimeric multiple antigenic peptides (CMAP) for simultaneous detection of specific antibodies to HIV-1 groups M, N, O, and HIV-2. Both CMAPs correctly identified 304 known HIV positive serum or plasma specimens (260 HIV-1 group M of varying subtypes, 3 group O, and 41 HIV-2) and one chimpanzee serum specimen (group N) and all 66 known HIV negative specimens. CMAP performance was superior to the corresponding individual linear peptides or a linear peptide mixture. The results indicate that CMAPs are useful for the development of highly sensitive and specific assays for the detection of infections caused by HIV-1, including group M, N, and O, and HIV-2.
Assuntos
Anticorpos Antivirais/sangue , Antígenos/imunologia , HIV-1/imunologia , HIV-2/imunologia , Peptídeos/imunologia , Sequência de Aminoácidos , Anticorpos Antivirais/imunologia , Antígenos/química , Ensaio de Imunoadsorção Enzimática/métodos , HIV-1/classificação , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Dados de Sequência Molecular , Peptídeos/síntese química , Peptídeos/química , Reprodutibilidade dos Testes , Vírus da Imunodeficiência Símia/imunologiaRESUMO
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) viral load has become a standard of care among HIV-1-infected patients; however, a small number of patients have undetectable viral load even though they have never been treated. METHODS: By using RT-PCR and DNA-PCR, and followed by sequencing and phylogenetic analyses, a detailed molecular characterization was carried out from five HIV-1-seropositive patients who had undetectable viral load by commercially available ultrasensitive viral load assays. RESULTS: Of the four patients whose plasmas were available, viral RNAs were detected in three of them by using an in-house RT-PCR in at least one of the three regions (integrase, protease or envgp41). The fourth patient had positive RT-PCR signals in these regions only when RNA isolated from the supernatant of cocultivated patient PBLs with PHA-stimulated HIV-1 negative donor PBLs was used. Further analysis of DNA extracted from the PBMCs revealed that four of the five patients had detectable proviral sequences in at least two of the three regions. The fifth patient had only positive PCR results in all three regions when DNA isolated from PHA-stimulated patient's PBLs was used. Phylogenetic analysis of protease and envgp41 regions revealed that three patients were infected with subtype B viruses while the remaining two patients were infected with subtype C and CRF02_AG viruses. These subtypes coincided with geographic origin and known molecular epidemiology of HIV-1 infection. CONCLUSION: These data provide evidence that both subtype B and non-B HIV-1 infection can result in undetectable viral load in HIV-1-infected patients and that efforts should continue to further characterize these viruses.
Assuntos
Anticorpos Anti-HIV/sangue , Infecções por HIV/diagnóstico , Soropositividade para HIV/virologia , HIV-1/classificação , HIV-1/isolamento & purificação , Adulto , Idoso , DNA Viral/análise , Feminino , Infecções por HIV/virologia , HIV-1/genética , Humanos , Masculino , Pessoa de Meia-Idade , Filogenia , RNA Viral/análise , Análise de Sequência de DNA , Carga Viral , Viremia/virologiaRESUMO
Rapid HIV antibody tests (RT) now permit HIV screening in settings where laboratory personnel may not be available. This study assessed the ability of 99 individuals with no laboratory experience to conduct two RT, OraQuick and Hema-Strip; these results were compared with those generated by laboratory professionals. All participants received written instructions and one-half also received a short demonstration. Error rates ranged from 2.1% to 4.6% with or without a demonstration. However, the number of invalid tests was greatly reduced when participants received a demonstration. Appropriate RT training for non-laboratorians and continued monitoring of HIV RT performance in non-laboratory settings is recommended.